Glial cell line-derived neurotrophic factors (GFLs) and small molecules targeting RET receptor for the treatment of pain and Parkinson's disease.

Mahato, Arun Kumar; Sidorova, Yulia A

Mahato, Arun Kumar; Sidorova, Yulia A.

Affiliation

Mahato AK; Institute of Biotechnology, HiLIFE, University of Helsinki, Viikinkaari 5D, 00014, Helsinki, Finland.
Sidorova YA; Institute of Biotechnology, HiLIFE, University of Helsinki, Viikinkaari 5D, 00014, Helsinki, Finland. yulia.sidorova@helsinki.fi.

Cell Tissue Res ; 382(1): 147-160, 2020 Oct.

Article in En | MEDLINE | ID: mdl-32556722

Subject(s)

Neuralgia/therapy; Parkinson Disease/genetics; Proto-Oncogene Proteins c-ret/genetics; Animals; Drug Design; Humans; Mice; Signal Transduction

Key words

Drug design; Drug development; GDNF family ligands (GFLs); Glial cell line-neurotrophic factor (GDNF); Neurturin (NRTN); RET agonist; RET receptor tyrosine kinase; RET receptor, artemin (ARTN); Small molecule

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Parkinson Disease / Proto-Oncogene Proteins c-ret / Neuralgia Type of study: Prognostic_studies Limits: Animals / Humans Language: En Year: 2020 Type: Article

Fulltext

XML

PubMed Links

Search on Google